National Pharmaceuticals Pricing Policy: A Review

Anika Sulania

Abstract


Like many other developing and a few developed countries, India also partly depends on pharmaceutical companies for its economic growth. Realizing the concept along with the need to provide accessible and affordable essential drugs to the citizens, especially those of economical weaker section, many drugs or pharmaceutical policies were formulated in India. Such policies ensure continuous availability of safe and effective essential medicines, especially in the public sector and quality, safety and efficacy of human and veterinary drugs inline with internationally acceptable standards while ensuring appropriate regulation and control, latest being the National Pharmaceutical Pricing Policy (NPPA), 2013, the focus of which is to include more drugs under NLEP, decrease in cost of medicines, providing generic medicines, etc. The use of the international non-proprietary name (INN), or generic name, is a recognized strategy to reduce medicine costs and expenditure. The policy though up to certain level provided the relief in the cost of essential medicines but still major areas were still untouched by the policy. This article deals with the drawback of the pharmaceutical policies in our country. Also the major problems being faced by the doctors who are part of government healthcare system and a vision of how to deal with it or what more can be added in such policies to provide the smooth and effective basic healthcare to the community.


Full Text:

PDF

References


Government of India. National pharmaceuticals pricing policy, 2012 .The Gazette of India, Part 1, Section 1; 2012. 2. Government of India. Drug policy, Ministry of Chemicals & Fertilizers. India 1986 Government notifies new drug pricing policy, cheaper drugs on way. Financial Express 13 Dec, 2012. Available at: http://www.financialexpress.com/news/governmen t-notifies-new-drug-pricing- policy cheaper [accessed on Oct 1, 2016]. 3. Government of India. Drug policy, Ministry of Chemicals & Fertilizers. India 2013. 4. Golechha M. Healthcare agenda for the Indian government. Indian J Med Res 2015; 141: 151-53. 5. Government of India. National health policy draft. Ministry of Health and Family Welfare, Government of India, New Delhi. 2014. 6. Government of India. Department of Pharmaceuticals. Ministry of Chemicals & Fertilizers. Annual Report 2015-16. 7. Danzon M, Chao L. Does regulation drive out competition in pharmaceutical markets? Journal of Law and Economics 2011; 43(2): 311-58. 8. Danzon M, Wang Y, Wang L. The impact of price regulation on the launch delay of new drugsevidence from twenty five major markets in 1990s.

Health Economics 2005; 14(3); 269-92. 9. Danzon M, Ketcham D. Reference pricing of pharmaceuticals for medicare: Evidence from Germany and the Netherlands and New Zealand. Frontiers in health policy research 2003: 7; 1-54. 10. Acemoglu D, Linn J. Market size in innovation: Theory and evidence from the pharmaceutical industry. National Bureau of Economic Research 2003; 119: 1049-90. 11. World Health Organization. Global health observatory data 2016 (Internet). (cited Oct 3, 2016). Available from: http://www.who.int/gho/ healthfinancing/out_out_pocket_expenditure/en/& rqid=e1ngbu7W&geid=he2010/en/ 12. Andriollo O, Machuron L, Videau JY et al. Supplies for humanitarian aid and development countries: The quality of essential multisource drugs. S.T.P. Pharma Pratiques1998; 8: 137-55. 13. Food & Drug Administration, Generic Drugs: Questions and Answers. Jan 12, 2010. [Retrieved Oct 3, 2016]. Available from: http://www.fda.gov/ Drugs/ResourcesForYou/Consumers/BuyingUsingM edicineSafely/UnderstandingGenericDrugs/ucm167 991.htm. 14. World Health Organization. WHO Guidelines on Country Pharmaceutical Pricing Policies. WHO. Geneva. 2015.


Refbacks

  • There are currently no refbacks.

Comments on this article

View all comments


Copyright (c) 2016 Journal of Advanced Research in Pharmaceutical Sciences & Pharmacology Interventions